Aug. 14, 2025
| This week’s gene therapy news and insights for biopharma leaders
Liquidating its stake in Arrowhead helps Sarepta cover a milestone payment and secure what one analyst described as “additional breathing room” ahead of a debt maturity in 2027.
|
With a strong launch underway for a bladder cancer gene therapy, Ferring is finding the kind of commercial success that’s eluded many of its peers.
|
UPDATED
One analyst speculated that, going forward, Prasad may be less “heavy-handed” in reviewing rare disease therapies given the public backlash to the agency’s confrontation with Sarepta.
|
The story of the rare disease market in recent years has been centered around growth with large pharmas starting to see more promise in the space as deals tick up. Learn more in
|
The fundraise will help advance a cancer therapy that’s already shown early promise in people whose cancers haven’t responded to drugs like Keytruda.
|
News roundup
Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.
|
What We're Reading
Endpoints
|
Nola.com
|
Genetic Engineering & Biotechnology News
|
Dive Into a Topic
|